Research & Development World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • Educational Assets
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE

Diseases of aging map to a few “hotspots” on the human genome

By R&D Editors | September 19, 2012

Researchers
have long known that individual diseases are associated with genes in
specific locations of the genome. Genetics researchers at the University
of North Carolina School of Medicine now have shown definitively that a
small number of places in the human genome are associated with a large
number and variety of diseases. In particular, several diseases of aging
are associated with a locus which is more famous for its role in
preventing cancer.

For
this analysis, researchers at UNC Lineberger Comprehensive Cancer
Center cataloged results from several hundred human Genome-Wide
Association Studies (GWAS) from the National Human Genome Research
Institute.  These results provided an unbiased means to determine if
varied different diseases mapped to common ‘hotspot’ regions of the
human genome. This analysis showed that two different genomic locations
are associated with two major subcategories of human disease.

“Our
team is interested in understanding genetic susceptibility to diseases
associated with aging, including cancer,” said PhD student William Jeck,
who was first author on the study, published in the journal Aging Cell.
 

The
team examined the large NHGRI dataset and first eliminated hereditable
traits such as eye or hair color and other non-disease traits like drug
metabolism. The group then focused on variants identified from GWAS that
contributed to actual diseases. Combining results from all of these
studies, there was enough data to arrive at statistically valid
conclusions. The team then mapped the disease associations to the
appropriate locations of the genome, counting the number of unique
diseases mapping to specific genomic regions, in order to see if
disparate diseases mapped randomly throughout the genome, or clustered
in hotspots.

“What
we ended up with is a very interesting distribution of disease risk
across the genome. More than 90% of the genome lacked any disease loci.
Surprisingly, however, lots of diseases mapped to two specific loci,
which soared above all of the others in terms of multi-disease risk.
 The first locus at chromosome 6p21, is where the major
histocompatibility (MHC) locus resides. The MHC is critical for tissue
typing for organ and bone marrow transplantation, and was known to be an
important disease risk locus before genome-wide studies were available.
Genes at this locus determine susceptibility to a wide variety of
autoimmune diseases such as arthritis, celiac disease, Type I diabetes,
asthma, psoriasis, and lupus,” said Jeck.

“The
second place where disease associations clustered is the INK4/ARF (or
CDKN2a) tumor suppressor locus.  This area, in particular, was the
location for diseases associated with aging: atherosclerosis, heart
attacks, stroke, Type II diabetes, glaucoma and various cancers,” he
added.

“The
finding that INK4/ARF is associated with lots of cancer, and MHC is
associated with lots of diseases of immunity is not surprising—these
associations were known.  What is surprising is the diversity of
diseases mapping to just two small places: 30% of all tested human
diseases mapped to one of these two places.  This means that genotypes
at these loci determine a substantial fraction of a person’s resistance
or susceptibility to multiple independent diseases,” said Ned Sharpless,
MD, Wellcome Distinguished Professor of Cancer Research and Associate
Director of Translational Research at UNC Lineberger.

Another
interesting finding was the apparent role of two biological processes
in multi-disease association.  In addition to the MHC and INK4/ARF loci,
five less significant hotspot loci were also identified. Of the seven
total hotspot loci, however, all contained genes associated with either
immunity or cellular senescence. Cellular senescence is a permanent form
of cellular growth arrest, and it is an important means whereby normal
cells are prevented from becoming cancerous. It has been long known that
senescent cells accumulate with aging, and may cause aspects of aging.
This new analysis provides evidence that genetic differences in an
individual’s ability to regulate the immune response and activate
cellular senescence determine their susceptibility to many seemingly
disparate diseases.   

“We
call the absence of disease ‘wellness’, and our results suggest the
genetics of wellness may be much more simple than previously suspected.
Put another way, these unbiased data from about two million people
suggest that your eccentric Uncle Joe, who drank and smoked, but who
also lived to be 110 and was never sick a day in his life—well Uncle Joe
may have just been genetically fortunate at a couple of loci,” said
Sharpless.

Alex
Siebold, PhD also worked on the research team. The study was supported
by the Burroughs Wellcome Fund and the National Institute of Aging
(AG024379).

Source: University of North Carolina Healthcare

Related Articles Read More >

For the first time, scientists grow beating human-pig hearts for 21 days
Open-source Boltz-2 can speed binding-affinity predictions 1,000-fold
Thermo Fisher’s new Orbitrap Excedion Pro targets complex biotherapeutics for drug development
FDA’s new ‘Elsa’ AI set to expedite clinical protocol reviews
rd newsletter
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest info on technologies, trends, and strategies in Research & Development.
RD 25 Power Index

R&D World Digital Issues

Fall 2024 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R&D magazine today.

Research & Development World
  • Subscribe to R&D World Magazine
  • Enews Sign Up
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • Global Funding Forecast

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • Educational Assets
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE